The Strata Trial will substantially reduce the time to new drug approvals for our pharma partners by increasing patient access to tumor sequencing and enrollment in precision oncology clinical trials.
The Strata Advantage
Our business model offers a competitive advantage and focuses on what matters most to our pharma partners: patient enrollment and accelerated drug approval.
We provide large-scale sequencing at concentrated clinical site networks, and a portfolio of targeted therapy trials, to drive clinical site participation and increase trial enrollment.
Our dramatically expanded reach enables us to identify sufficient mutation-positive patients to design and conduct transformative precision oncology trials.
We accelerate drug approval by efficiently matching our pharma partners' targeted therapies with mutation-matched patients.
We are interested in partners with programs targeting alterations in the following genes: ALK, AKT1, BRCA1/2, BRAF, EGFR, ERBB2/3, EZH2, FGFR1-4, IDH1/2, KRAS, MAP2K1, MET, NTRK1-3, ROS1, RET
We are also interested in partners with immuno-oncology programs targeting biomarker-defined populations (e.g. high tumor mutation burden, immune response markers).
Contact us to discuss how Strata can help accelerate your precision oncology trial.